Enanta Pharmaceuticals Inc (ENTA): who owns it and who trades it
As of Nov 16, 2026, ENTA insiders reported 9 open-market sales worth $183K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jay R. Luly (CEO), with $67.5K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Enanta Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ENTA
121 funds and institutions reported ENTA shares worth $402M at the end of Q2 2026, about 95% of the company. The largest holder is Jupiter Topco LLC with 12.6%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 3.65M | 12.57% | $53.3M | – |
| BlackRock, Inc. | 3.24M | 11.16% | $47.3M | +5% |
| Krensavage Asset Management, LLC | 2.87M | 9.86% | $41.8M | No change |
| Farallon Capital Management, L.l.c. | 2.42M | 8.32% | $35.3M | -16% |
| Deep Track Capital, LP | 1.44M | 4.97% | $21.1M | -26% |
| ADAR1 Capital Management, LLC | 1.34M | 4.62% | $19.6M | +2518% |
| Vanguard Capital Management LLC | 1.21M | 4.17% | $17.7M | +3% |
| Spruce Street Capital LP | 1.09M | 3.74% | $15.9M | +17% |
| Acadian Asset Management LLC | 1.08M | 3.71% | $15.7M | +23% |
| Vanguard Portfolio Management LLC | 1.01M | 3.48% | $14.7M | +7% |
| Geode Capital Management, LLC | 776,634 | 2.67% | $11.3M | +7% |
| Millennium Management LLC | 643,967 | 2.21% | $9.4M | -27% |
| State Street Corp | 576,117 | 1.98% | $8.4M | +2% |
| Renaissance Technologies LLC | 557,600 | 1.92% | $8.1M | -16% |
| Hillsdale Investment Management Inc. | 468,000 | 1.61% | $6.8M | +7% |
| Goldman Sachs Group Inc | 464,649 | 1.60% | $6.8M | +75% |
| Morgan Stanley | 315,729 | 1.09% | $4.6M | +2% |
| Charles Schwab Investment Management Inc | 301,151 | 1.04% | $4.4M | +2% |
| Sixth Street Partners Management Company, L.P. | 301,151 | 1.04% | $4.4M | – |
| Dimensional Fund Advisors LP | 282,682 | 0.97% | $4.1M | +39% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ENTA insiders reported $0 of open-market purchases and $183K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Kathleen S. Capps | See Remarks | Sale | 323 | $14.23 | $4.6K | Form 4 |
| Dec 5, 2025 | Harry R. Trout III | See Remarks | Sale | 542 | $14.23 | $7.7K | Form 4 |
| Dec 5, 2025 | Scott T. Rottinghaus | Chief Medical Officer | Sale | 798 | $14.23 | $11.4K | Form 4 |
| Dec 5, 2025 | Brendan Luu | Chief Business Officer | Sale | 1,394 | $14.23 | $19.8K | Form 4 |
| Dec 5, 2025 | Tara Lynn Kieffer | Chief Product Strategy O | Sale | 2,106 | $14.23 | $30K | Form 4 |
| Dec 5, 2025 | Yat Sun Or | Chief Scientific Officer | Sale | 2,390 | $14.23 | $34K | Form 4 |
| Dec 5, 2025 | Jay R. Luly | CEO | Sale | 4,743 | $14.23 | $67.5K | Form 4 |
| Dec 2, 2025 | Kathleen S. Capps | See Remarks | Sale | 207 | $13.96 | $2.9K | Form 4 |
| Dec 2, 2025 | Harry R. Trout III | See Remarks | Sale | 380 | $13.96 | $5.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jay R. Luly | President and CEO, Director | – | $67.5K | Dec 5, 2025 |
| Yat Sun Or | Chief Scientific Officer | – | $34K | Dec 5, 2025 |
| Tara Lynn Kieffer | Chief Product Strategy Officer | – | $30K | Dec 5, 2025 |
| Brendan Luu | Chief Business Officer | – | $19.8K | Dec 5, 2025 |
| Harry R. Trout III | See Remarks | – | $13K | Dec 5, 2025 |
| Scott T. Rottinghaus | Chief Medical Officer | – | $11.4K | Dec 5, 2025 |
| Kathleen S. Capps | See Remarks | – | $7.5K | Dec 5, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ENTA short interest
Moderate short interest. 6.4% of ENTA shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.86M ENTA shares were sold short, 6.4% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 243,263 shares, buying them all back would take about 7.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.86M | 6.37% | -18% | 243,263 | 7.6 |
| Oct 15, 2026 | 2.27M | 7.78% | -11% | 264,255 | 8.6 |
| Sep 30, 2026 | 2.55M | 8.77% | -2% | 277,685 | 9.2 |
| Sep 15, 2026 | 2.60M | 8.93% | -1% | 242,451 | 10.7 |
| Aug 31, 2026 | 2.62M | 8.98% | -2% | 257,672 | 10.2 |
| Aug 14, 2026 | 2.68M | 9.20% | +4% | 181,762 | 14.7 |
| Jul 31, 2026 | 2.59M | 8.90% | +6% | 146,348 | 17.7 |
| Jul 15, 2026 | 2.44M | 8.40% | -6% | 191,239 | 12.8 |
| Jun 30, 2026 | 2.58M | 8.88% | +6% | 319,284 | 8.1 |
| Jun 15, 2026 | 2.43M | 8.35% | +7% | 189,612 | 12.8 |
| May 29, 2026 | 2.27M | 7.82% | +3% | 207,421 | 11.0 |
| May 15, 2026 | 2.20M | 7.58% | +2% | 235,034 | 9.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Enanta Pharmaceuticals company events
Enanta Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026AnnouncementAs previously disclosed, Enanta Pharmaceuticals, Inc. filed a patent infringement action in the Unified Patent Court of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 in connection… Filing
- Oct 28, 2026LeadershipEnanta Pharmaceuticals, Inc. and Jay R. Luly, Ph.D., age 70, announced Dr. Luly’s intention to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AgreementEnanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement SM with Jefferies LLC, as sales agent, pursuant to which the Corporation may offer and sell shares of its common stock, $0.01 par value per share, from time to time through the Agent. Filing
- Jun 23, 2026AnnouncementAs previously disclosed by Enanta Pharmaceuticals, Inc., the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture, use, and sale of… Filing
- Jun 18, 2026AnnouncementShared information with investors. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 26, 2026AnnouncementAs previously disclosed by Enanta Pharmaceuticals, Inc., on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the… Filing
- Mar 12, 2026LeadershipAs disclosed below under Item 5.07, on March 11, 2026, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. Filing
- Feb 9, 2026ResultsReleased financial results. Filing
- Nov 17, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Enanta Pharmaceuticals financials
Famous investors that hold ENTA
5 of the 50 well-known investors we track reported holding ENTA in their latest 13F filing. The largest position is Israel Englander's, worth $10.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 774,748 | $10.2M | 0.0% | +20% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 473,000 | $6.2M | 0.0% | -15% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 138,638 | $1.8M | 0.0% | +173% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 47,094 | $621K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 10,443 | $138K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ENTA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 6.0% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G | 6.0% |
| Nov 16, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 3.3% |
| Nov 16, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 3.3% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.4% |
| Oct 27, 2026 | BlackRock Portfolio Management LLC | 13G | 5.4% |
Questions about Enanta Pharmaceuticals Inc (ENTA) stock
Who owns the most ENTA stock?
The largest reported owner of Enanta Pharmaceuticals Inc (ENTA) is Jupiter Topco LLC, with 12.6% of the company. In total, 121 funds and institutions reported holding ENTA at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are ENTA insiders buying or selling?
In the last 12 months, ENTA insiders reported no open-market purchases and 9 sales worth $183K. The latest trade was on Dec 5, 2025. See every trade.
What is the short interest in ENTA?
As of Oct 30, 2026, 1.86M ENTA shares were sold short, 6.4% of the shares outstanding, down 18.0% from the report before. At the average daily volume of 243,263 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.
Which famous investors hold ENTA?
5 of the 50 well-known investors we track reported ENTA in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $10.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.